Siglec-2 Protein - ACROBiosystems

Siglec-2

Siglec-2 Molecule Information

Name：CD22
Target Synonym：SIGLEC2?B-lymphocyte cell adhesion molecule?Sialic acid-binding Ig-like lectin 2?Siglec-2?CD_antigen=CD22?T-cell surface antigen Leu-14?CD22?BL-CAM?B-cell receptor CD22

Number of Launched Drugs：2
Number of Drugs in Clinical Trials：30
Lastest Research Phase：Approved

Siglec-2 Protein Product ListCompare or Buy


SI2-HF2H6	Human	FITC-Labeled Human Siglec-2 / CD22 Protein, His Tag
SI2-H525a	Human	Human Siglec-2 / CD22 Protein, Llama IgG2b Fc Tag, low endotoxin
SI2-R52Ha	Rhesus macaque	Rhesus macaque Siglec-2 / CD22 Protein
SI2-M52Ha	Mouse	Mouse Siglec-2 / CD22 Protein
SI2-H82F8	Human	Biotinylated Human Siglec-2 / CD22 Protein, Fc,Avitag™
CD2-H52H8	Human	Human Siglec-2 / CD22 Protein, His Tag
SI2-H5228	Human	Human Siglec-2 / CD22 (176-687) Protein, His Tag

Cat. No.

Species

Product Description

Structure

Purity

Feature

SI2-HF2H6

Human

FITC-Labeled Human Siglec-2 / CD22 Protein, His Tag

SI2-H525a

Human

Human Siglec-2 / CD22 Protein, Llama IgG2b Fc Tag, low endotoxin

SI2-R52Ha

Rhesus macaque

Rhesus macaque Siglec-2 / CD22 Protein

SI2-M52Ha

Mouse

Mouse Siglec-2 / CD22 Protein

SI2-H82F8

Human

Biotinylated Human Siglec-2 / CD22 Protein, Fc,Avitag™

CD2-H52H8

Human

Human Siglec-2 / CD22 Protein, His Tag

SI2-H5228

Human

Human Siglec-2 / CD22 (176-687) Protein, His Tag

Siglec-2 Molecule Synonym Name

CD22,SIGLEC2,BL-CAM,Leu-14

Siglec-2 Molecule Background

B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Siglec-2 References

Siglec-2 Public Drug Information

Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Moxetumomab pasudotox	CAT-8015; GCR-8015; HA-22,CAT8015,GCR8015, HA22	Approved	AstraZeneca	LUMOXITI	fda		ASTRAZENECA AB	2018-09-13	Hairy cell leukemia	Details
Inotuzumab Ozogamicin	CMC-544; PF-5208773; WAY-207294,CMC544,PF5208773,WAY207294	Approved	Pfizer, UCB	inotuzumab ozogamicin	ema		Pfizer Europe MA EEIG	2017-06-28	Acute lymphoblastic leukaemia (ALL)	Details

Siglec-2 Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
CD22-CART		Phase Ⅰ	Shanghai Hrain Biotechnology	Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma	Details
AUT-O3	AUTO-3	Phase Ⅱ	University College London, Autolus	B-cell lymphoma, Acute lymphoblastic leukaemia (ALL)	Details
Anti-CD22 CAR-T cell therapy (No. 307 Hospital)		Phase Ⅱ	No 307 Hospital of the Chinese People’s Liberation Army	Acute lymphoblastic leukaemia (ALL)	Details
SM-03	SM-03; SM-06	Phase Ⅱ	Lonn Ryonn Pharma, SinoMab Bioscience Ltd	Systemic lupus erythematosus, Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL)	Details
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech)	LCAR-L10D	Phase Ⅰ	Second Affiliated Hospital of Xi'an Jiaotong University, Nanjing Legend Biotech	Diffuse large B cell lymphoma	Details
JCAR-018	JCAR-018	Phase Ⅰ	National Cancer Institute, Opus Bio, Juno Therapeutics	Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas	Details
BAY-1862864	BAY-1862864	Phase Ⅰ	Bayer	Non-Hodgkin's lymphoma (NHL)	Details
Epratuzumab	AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2,AMG412,CDP3194,IMMU103,IMMU1903,IMMUhLL2	Phase Ⅲ	Immunomedics, UCB	Sjoegren's syndrome, Systemic lupus erythematosus, Acute lymphoblastic leukaemia (ALL)	Details
GTB-1550	DT-2219ARL; DT-2219; IND-100780; OXS-1550	Phase Ⅱ	University of Minnesota, Oxis International, GT Biopharma	B-cell lymphoma, Leukemia	Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate		Phase Ⅰ	University of Texas Southwestern Medical Center, Galileo Research	B-cell lymphoma, Acute lymphoblastic leukaemia (ALL)	Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital)		Phase Ⅱ	General Hospital of the People's Liberation Army	B-cell lymphoma, Leukemia	Details
Epratuzumab I-131		Phase Ⅱ	Immunomedics, Repligen	Non-Hodgkin's lymphoma (NHL)	Details
UCART-22	UCART-22	Phase Ⅰ	Cellectis	Acute lymphoblastic leukaemia (ALL)	Details
Pinatuzumab vedotin	DCDT-2980S; FCU-2703; RG-7593; RO-5541072; RO-5541072-000; ACD22-VCMMAE	Phase Ⅱ	Genentech	Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL)	Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital)		Phase Ⅰ	Seattle Children's Hospital	Acute lymphoblastic leukaemia (ALL)	Details
Anti-CD22 CAR T cell therapy (Shanghai GeneChem)		Phase Ⅰ	Shanghai GeneChem	Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas	Details
Bectumomab		Phase Ⅲ	Immunomedics	Non-Hodgkin's lymphoma (NHL)	Details
CART22-cells	CART22-cells	Phase Ⅰ	University of Pennsylvania, Novartis	B-cell lymphoma, Leukemia	Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University)		Phase Ⅰ	Shanghai Jiaotong University	Acute lymphoblastic leukaemia (ALL)	Details
Chimeric antigen receptor T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine)		Phase Ⅱ	Shanghai Unicar-Therapy Bio-medicine Technology	Lymphoblastic leukaemia, Multiple myeloma (MM), Acute lymphoblastic leukaemia (ALL), Lymphoma, Non-Hodgkin's lymphoma (NHL), Pancreatic cancer	Details
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid)		Phase Not Specified	Wuhan Bio-Raid Biotechnology	B-cell lymphoma, Multiple myeloma (MM)	Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University)		Phase Ⅰ	Stanford University	B-cell lymphoma	Details
Epratuzumab Y-90	90Y-DOTA-hLL2; 90Y-hLL2; hCD22-Y-90; IMMU-102	Phase Ⅱ	Immunomedics, Nantes University Hospital	Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL)	Details
Anti-CD22 monoclonal antibody-toxin conjugate (Galileo Research/the University of Texas)	IMTOX-22	Phase Ⅰ	University of Texas Southwestern Medical Center, Royal Free and University College Medical School, Cancer Research Technology, National Institutes of Health, Galileo Research, Abiogen Pharma	Non-Hodgkin B-cell lymphomas	Details
CAT-3888	CAT-3888; BL-22	Phase Ⅱ	Cambridge Antibody Technology, National Institutes of Health, MedImmune	Lymphoblastic leukaemia, Chronic lymphocytic leukemia (CLL), Hairy cell leukemia, Non-Hodgkin's lymphoma (NHL)	Details
RFB4-SMPT-dgA	RFB4-SMPT-dgA; IgG-RFB4-SMPT-dgA; NSC639179	Phase Ⅰ	National Cancer Institute, University of Texas Southwestern Medical Center	B-cell lymphoma	Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital)		Phase Ⅰ	General Hospital of the People's Liberation Army	Leukemia, Lymphoma	Details
TRPH-222	TRPH-222; CAT-02-106; CD22-4AP	Phase Ⅰ	Catalent, Triphase Accelerator	B-cell lymphoma	Details
Anti-CD22 CAR-T cell therapy (iCarTAB BioMed)		Phase Ⅱ	iCarTAB Biomed	B-cell lymphoma	Details
Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology)		Phase Ⅰ	Yake Biotechnology, The First Affiliated Hospital of Zhejiang University School of Medicine, Beijing Boren Hospital	Lymphoblastic leukaemia, hematological malignancies	Details